Tag: Drug discovery

Approximately one-third of individuals diagnosed with epilepsy will not achieve full seizure control with available medications. This challenge, known as drug-resistant epilepsy, highlights the fundamental question of **why do so many epilepsy drugs fail**, and it points toward the intricate biological and clinical factors at play.

In the early 20th century, the discovery and mass production of penicillin transformed medicine, curing thousands of once-fatal bacterial infections and leading many to call it the first "miracle drug". But as pharmacology has evolved, the question of **what is the miracle drug?** has become less about a single cure and more about how medical innovation changes our lives.

According to the World Economic Forum, by 2025, artificial intelligence (AI) is estimated to drive 30% of new drug discoveries, highlighting its pivotal role in reshaping the pharmaceutical landscape. In response to technological innovation and evolving patient needs, understanding what are the trends in pharma industry 2025 is essential for navigating this transformative era.

According to scientific literature, antibiotic resistance through target modification is a prevalent strategy employed by pathogens to evade treatment. Understanding what is modification of the drug target is thus essential for grasping the complexities of both disease-causing organisms and modern medicinal chemistry.

First discovered from a microbe in a Japanese soil sample, the precursor to ivermectin is indeed a natural product. However, the final antiparasitic medication, ivermectin, is not purely natural but a semisynthetic derivative, created through a specific chemical modification process.

According to physician perception, new pharmaceuticals and biopharmaceuticals were the biggest contributors to improved health outcomes for eight debilitating diseases over a 20-year period. So, **what does a medical breakthrough offer** beyond incremental progress, providing revolutionary changes that can fundamentally alter a patient's life and the healthcare landscape? It offers unprecedented hope and transformative new possibilities.

Developed by the Swiss pharmaceutical company Novartis, the groundbreaking biologic Cosentyx, or **secukinumab**, was the first interleukin-17A (IL-17A) inhibitor to receive FDA approval, marking a significant advancement for treating autoimmune and inflammatory diseases. Its development was a long process involving extensive research into inflammatory pathways.

Introduced in 1910, Salvarsan was celebrated as the first effective treatment for syphilis, but it was an arsenic-based drug known for its severe side effects and challenging administration. This made the advent of a safer, more potent alternative inevitable, ultimately explaining why penicillin replaced Salvarsan as the superior treatment option in the mid-20th century.

Over its 175-year history, Pfizer has evolved from a small chemical manufacturer to a global biopharmaceutical leader, delivering breakthroughs that have changed billions of patient lives. This extensive history showcases exactly what has Pfizer achieved in the fields of medications and pharmacology, with impacts spanning from antibiotics to cutting-edge cancer treatments.

While the lotus has been revered in traditional medicine for millennia, specific compounds rather than the plant itself are under modern pharmacological investigation to determine **what drug is made from lotus**. The primary psychoactive compounds, nuciferine and apomorphine, hold significant interest for potential development into pharmaceutical drugs.